Oxidative stress, endothelial dysfunction and cerebrovascular disease

Cerebrovascular Diseases

Volumn 24, Issue SUPPL. 1, 2007, Pages 24-29

  Zalba, Guillermo ^a   Fortuño, Ana ^a   San José, Gorka ^a   Moreno, María U ^a   Beloqui, Oscar ^b   Díez, Javier ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Atherosclerosis; Endothelial dysfunction; Oxidative stress; Phagocytic cells

Indexed keywords

NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; DISEASE CONTROL; DISEASE COURSE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENZYME METABOLISM; ENZYME SYNTHESIS; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROPHYLAXIS; SCAVENGING SYSTEM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; OXIDATIVE STRESS; PHAGOCYTES;

EID: 35648964647     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107376     Document Type: Conference Paper

References (44)

1. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, Goto S, Liau C-S, Richard AJ, Röther J, Wilson PWF, for the REACH Registry Investigators: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherosclerosis. JAMA 2006;295:180-189.
2. Sacco RL: Newer risk factors for stroke. Neurology 2001;57(5 suppl 2):S31-S34.
3. Cosentino F, Rubattu S, Savoia C, Venturelli V, Pagannonne E, Volpe M: Endothelial dysfunction and stroke. J Cardiovasc Pharmacol 2001;38(suppl 2):S75-S78.
4. Blanco M, Rodriguez-Yanez M, Sobrino T, Leira R, Castillo J: Platelets, inflammation, and atherothrombotic neurovascular disease: the role of endothelial dysfunction. Cerebrovasc Dis 2005;20(suppl 2):32-39.
5. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H: Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A.
6. Landmesser U, Harrison DG, Drexler H: Oxidant stress - A major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 2006;62(suppl 13):13-19.
7. Babior BM: NADPH oxidase: an update. Blood 1999;93:1464-1476.
8. Johnson F, Giulivi C: Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005;26:340-352.
9. Kojda G, Harrison D: Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999;43:562-571.
10. Vasquez-Vivar J, Kalyanaraman B, Martasek P: The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 2003;37:121-127.
11. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;5:C1424-C1437.
12. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
13. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
14. Kalinina N, Agrotis A, Tararak E, Antropova Y, Kanellakis P, Ilyinskava O, Quinn MT, Smirnov V, Bobik A: Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2002;22:2037-2043.
15. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK: Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002;105:1429-1435.
16. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, Awano K, Kobayashi K, Maeda K, Hata K, Shinke T, Kobayashi S, Hirata K, Kawashima S, Itabe H, Hayashi Y, Imajoh-Ohmi S, Itoh H, Yokoyama M: Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2002;22:1838-1844.
17. Faraci FM, Didion SP: Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004;24:1367-1373.
18. Fukai T, Folz RJ, Landmesser U, Harrison DG: Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 2002;55:239-249.
19. Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B: Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000;101:2264-2270.
20. Kumar KV, Das UN: Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993;19:55-66.
21. Mehta JL, Lopez LM, Chen L, Cox OE: Alteration in nitric oxide synthase pathway, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 1994;74:901-905.
22. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S: Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998;11:921-928.
23. Kopprasch S, Graessler J, Seibt R, Naumann HJ, Scheuch K, Henssge R, Schwanebeck U: Leukocyte responsiveness to substances that activate the respiratory burst is not altered in borderline and essential hypertension. J Hum Hypertens 1996;10:69-76.
24. Seifert R, Higenstock G, Fassbender M, Distler A: Regulation of the superoxide-forming NADPH oxidase of human neutrophils is not altered in essential hypertension. J Hypertens 1991;9:147-153.
25. Fortuño A, Oliván S, Beloqui O, San JoséG, Moreno MU, Díez J, Zalba G: Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004;22:2169-2175.
26. Zalba G, San JoséG, Moreno MU, Fortuño A, Díez J: NADPH oxidase-mediated oxidative stress: genetic studies of the p22phox gene in hypertension. Antiox Redox Signal 2005;7:1327-1336.
27. Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT: Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003;41:1096-1101.
28. Pedro-Botet J, Covas MI, Martin S, Rubiés-Prat J: Decreased endogenous antioxidant enzymatic status in essential hypertension. J Hum Hypertens 2000;14:343-345.
29. Kedziora-Kornatowska K, Czuczejko J, Pawluk H, Kornatowski T, Motyl J, Szadujkis-Szadurski L, Szewczyk-Golek K, Kedziora J: The markers of oxidative stress and activity of the antioxidant system in the blood of elderly patients with essential arterial hypertension. Cell Mol Biol Lett 2004;9:635-641.
30. Polizio AH, Peña C: Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regul Pept 2005;128:1-5.
31. Tanaka M, Umemoto S, Kawahara S, Kubo M, Itoh S, Umeji K, Matsuzaki M: Angiotensin II type 1 receptor antagonist and angiotensin-converting enzyme inhibitor altered the activation of Cu/Zn-containing superoxide dismutase in the heart of stroke-prone spontaneously hypertensive rats. Hypertens Res 2005;28:67-77.
32. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G: Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: The Atherosclerotic Risk in Communities (ARIC) study. Stroke 1995;26:386-391.
33. Bots ML, Hoes AW, Kondstaal PJ, Hofman A, Grobbe DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-1437.
34. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G: Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerotic Risk in Communities (ARIC) study. Am J Epidemiol 2000;151:478-487.
35. Longstreth WT Jr, Shemanski L, Lefkowitz D, O'Leary DH, Polak JF, Wolfson SK Jr: Asymptomatic internal carotid artery stenosis defined by ultrasound and the risk of subsequent stroke in the elderly. The Cardiovascular Health Study. Stroke 1998;29:2371-2376.
36. Mancini GBJ, Dahlöf B, Díez J: Surrogate markers for cardiovascular disease. Structural markers. Circulation 2004;109(suppl IV):IV-22-IV-30.
37. Zalba G, Beloqui O, San JoséG, Moreno MU, Fortuño A, Díez J: NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005;25:1452-1457.
38. Fortuño A, San JoséG, Moreno MU, Beloqui O, Díez J, Zalba G: Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006;55:209-215.
39. Versari D, Herrmann J, Gossi M, Mannheim D, Sattler K, Meyer FB, Lerman LO, Lerman A: Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2132-2139.
40. Uno M, Kitazato KT, Suzue A, Itabe H, Hao L, Nagahiro S: Contribution of an imbalance between oxidant-antioxidant systems to plaque vulnerability in patients with carotid artery stenosis. J Neurosurg 2005;103:518-525.
41. Kakko S, Päivänsalo M, Koistinen P, Kesäniemi YA, Kinnula VL, Savolainen MJ: The signal sequence polymorphism of the Mn-SOD gene is associated with the degree of carotid atherosclerosis. Atherosclerosis 2003;168:147-152.
42. Shimoda-Maatsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene: A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 1996;226:561-565.
43. Violi F, Cangemi R: Antioxidants and cardiovascular disease. Curr Opin Invest Drugs 2005;6:895-890.
44. Guzik TJ, Harrison DG: Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006;11:524-533.